DocuSign Inc. reported strong first-quarter of fiscal 2026 results while unveiling an artificial intelligence strategy.

CEO Thygesen explained foundational go-to-market changes ... improving fundamentals and the absence of material demand issues. DocuSign management underscored rapid IAM adoption, robust Q1 ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

This adjustment reflects ongoing challenges faced by the company, including sales force productivity issues and ... its position as a market leader. In other recent news, DocuSign Inc (NASDAQ ...

In contrast, UBS analysts have adjusted their price target for Docusign to $85 from $90, maintaining a Neutral rating due to market conditions and customer budget concerns. Docusign’s leadership ...

Docusign DOCU will report first-quarter fiscal 2026 results on June 5, after market close ... s long-term growth prospects remain uncertain. Issues may arise if the product undergoes early ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

We came across a bearish thesis on DocuSign, Inc. (DOCU) on Deep Value Returns’ Substack. In this article, we will summarize ...

Docusign DOCU will report first-quarter fiscal 2026 results on June 5, after market close. The Zacks Consensus Estimate for ...

This edition of Market Factors includes a thematic investing approach uncovering stocks that outperform. New stresses in the ...

FDG offers a concentrated, high-growth portfolio with mega-cap tech, consumer discretionary, and healthcare overweights, but ...

Never mind the tariffs and tantrums. The 'dual equity pain trade' means new highs for stocks. Big investors find themselves underweight Big Tech as leadership narrows again, says JPMorgan The spat ...